ICH Q3C: Why Option 1's Table Isn't Your Real Ceiling

ICH Q3C sets permitted limits for residual solvents left over from drug substance and drug product manufacturing, and most specification files default to the same shortcut: pull the concentration limit straight from the guideline's Option 1 table. That table is real and it is usable — but it is built on a single assumption, a 10 gram per day product dose, that has nothing to do with your actual product. When the assumption doesn't hold, Option 1 is not a conservative fallback. It is either too strict or not strict enough, and the guideline provides the alternative calculation for exactly that reason.

What the three classes actually mean

Class 1 solvents are the ones ICH treats as known human carcinogens, strong suspected carcinogens, or environmental hazards — benzene is the standard example the guideline itself cites. The expectation is not a permitted concentration; it is avoidance, unless a sponsor can justify the use in a documented risk-benefit assessment. Class 2 covers solvents with real but lesser toxicity — neurotoxicity or reproductive toxicity, for example — where a permitted daily exposure defines how much is acceptable. Class 3 solvents have low toxic potential and carry a generous default: no health-based limit is required below 50 mg per day.

Where the default assumption breaks

A low-dose injectable or a potent oncology product dosed in milligrams per day is nowhere near Option 1's 10 gram assumption. Applying the table limit anyway can under-restrict a solvent relative to what the patient's actual exposure would justify treating more conservatively — and, just as often, it needlessly tightens a specification a manufacturer would pass easily under Option 2, forcing process changes that were never necessary. A high-dose oral solid, on the other end, can carry an actual daily dose well above 10 grams once every component is summed, in which case Option 1's table is not conservative enough on its own terms, and Option 2's dose-based calculation is the one the guideline actually expects.

• The solvent's permitted daily exposure (PDE), from the guideline's table, in milligrams per day.
• The product's actual maximum daily dose, not a rounded or assumed figure.
• Every component's contribution, summed — drug substance, excipients, and any process solvent introduced at any manufacturing stage.
• The resulting concentration limit, calculated per component, which can differ meaningfully from the Option 1 table figure in either direction.

Option 1 is a table you can look up. Option 2 is a calculation you have to run. The guideline doesn't tell you which one to use — it tells you which one is actually true for your product. Why the option isn't a formality

Building the option into the specification, not just the CMC section

The choice between Option 1 and Option 2 belongs in the same conversation as every other impurity threshold and mutagenic limit a CMC team sets — not as a one-time lookup at the first submission, but as a specification decision revisited when the dose, the formulation, or the manufacturing process changes. A method transfer, a new strength, or a route-of-administration change can each move a product far enough from the 10 gram assumption that a limit set under Option 1 years earlier no longer reflects the product being manufactured today. Pharmaceutical manufacturers running a CMC regulatory strategy that treats residual-solvent limits as a living specification, not a table lookup, catch that drift before an inspector or a reviewer does.

None of this is a reason to abandon Option 1 — for a product genuinely dosed near 10 grams a day, the table is the calculation, and running Option 2 anyway just reproduces the same number with more paperwork. The judgment call is knowing which situation you're actually in, and setting the specification — and the rationale behind it — accordingly rather than by default.